PT1686972E - Composição pulverizável para a administração de derivados da itamina d - Google Patents

Composição pulverizável para a administração de derivados da itamina d Download PDF

Info

Publication number
PT1686972E
PT1686972E PT04803732T PT04803732T PT1686972E PT 1686972 E PT1686972 E PT 1686972E PT 04803732 T PT04803732 T PT 04803732T PT 04803732 T PT04803732 T PT 04803732T PT 1686972 E PT1686972 E PT 1686972E
Authority
PT
Portugal
Prior art keywords
vitamin
administration
derivatives
sprayable composition
composition
Prior art date
Application number
PT04803732T
Other languages
English (en)
Inventor
Franck Pitre
Laurent Fredon
Claire Mallard
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0313660A external-priority patent/FR2862540B1/fr
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of PT1686972E publication Critical patent/PT1686972E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT04803732T 2003-11-21 2004-11-17 Composição pulverizável para a administração de derivados da itamina d PT1686972E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0313660A FR2862540B1 (fr) 2003-11-21 2003-11-21 Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
US54124504P 2004-02-04 2004-02-04

Publications (1)

Publication Number Publication Date
PT1686972E true PT1686972E (pt) 2008-04-23

Family

ID=34655190

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04803732T PT1686972E (pt) 2003-11-21 2004-11-17 Composição pulverizável para a administração de derivados da itamina d

Country Status (15)

Country Link
EP (2) EP1686972B1 (pt)
JP (1) JP2007511578A (pt)
AT (1) ATE388697T1 (pt)
AU (1) AU2004294728A1 (pt)
BR (1) BRPI0416311A (pt)
CA (1) CA2543577A1 (pt)
CY (1) CY1107942T1 (pt)
DE (1) DE602004012440T2 (pt)
DK (1) DK1686972T3 (pt)
ES (1) ES2302060T3 (pt)
MX (1) MXPA06005587A (pt)
PL (1) PL1686972T3 (pt)
PT (1) PT1686972E (pt)
RU (1) RU2006121973A (pt)
WO (1) WO2005053666A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480377A1 (en) 2002-03-26 2003-10-09 Teva Pharmaceutical Industries Ltd. Drug microparticles
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
AU2006256860B2 (en) * 2005-06-10 2012-04-19 Galderma S.A. Controlled release of a drug through skin on the basis of a topical composition comprising a drug, a film-forming silicone and at least one volatile solvent
FR2887150B1 (fr) * 2005-06-17 2007-08-03 Galderma Res & Dev Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
FR2893845B1 (fr) * 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un corticoide et une phase huileuse
RU2008142388A (ru) * 2006-04-03 2010-05-10 Тева Фармасьютикл Индастриес Лтд. (Il) Микрочастицы лекарственного вещества
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
HUP0900072A2 (hu) 2009-02-06 2010-09-28 Egis Gyogyszergyar Nyilvanosan Transzdermális gyógyszerkészítmények
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
CN102655869B (zh) 2009-08-14 2016-08-10 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
AU2012228273B2 (en) 2011-03-14 2015-08-20 Drug Delivery Solutions Limited An ophthalmic composition
CN112156097A (zh) * 2013-05-29 2021-01-01 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发
AU2014329421B2 (en) 2013-10-03 2018-08-02 Dow Pharmaceutical Sciences, Inc. Stabilized efinaconazole compositions
WO2015077729A2 (en) 2013-11-22 2015-05-28 Dow Pharmaceutical Sciences, Inc. Anti-infective methods, compositions, and devices
JP6972464B2 (ja) * 2015-12-18 2021-11-24 ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. 二芳香族ビタミンｄアナログ
WO2017102791A1 (en) * 2015-12-18 2017-06-22 Dsm Ip Assets B.V. Novel compounds
CN108366940B (zh) * 2015-12-18 2022-01-14 帝斯曼知识产权资产管理有限公司 联芳香族维生素d类似物
JP6972472B2 (ja) * 2015-12-18 2021-11-24 ディーエスエム アイピー アセッツ ビー.ブイ.Dsm Ip Assets B.V. 二芳香族ビタミンｄアナログ
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
US4525341A (en) * 1984-04-09 1985-06-25 Mayor Pharmaceutical Laboratories, Inc. Method of administering vitamins
US4889845A (en) * 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
FI872553A (fi) * 1986-06-09 1987-12-10 American Cyanamid Co Medium foer laekemedel foer lokalt bruk.
JPH02145512A (ja) * 1988-11-26 1990-06-05 Shin Etsu Chem Co Ltd 被膜形成型外用剤
GB9109733D0 (en) * 1991-05-07 1991-06-26 Unilever Plc Cosmetic composition
FR2719220A1 (fr) * 1994-04-29 1995-11-03 Lafon Labor Nouvelle forme galénique pour l'administration transdermique.
US6538039B2 (en) * 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
FR2740038B1 (fr) * 1995-10-20 1998-01-02 Lafon Labor Composition pour l'administration transdermique
FR2753626B1 (fr) 1996-09-20 1998-11-06 Centre International De Rech Dermatologiques Galderma Cird Galderma Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
FR2760971B1 (fr) * 1997-03-20 1999-12-10 Dow Corning Sa Procede de production d'une composition a liberation controlee
EP0966972B1 (en) * 1998-06-18 2003-09-24 Dow Corning France S.A. Topical composition containing silicon gum
GB9902812D0 (en) * 1998-06-18 1999-03-31 Dow Corning Sa Composition for delivering pharmaceutically active agents
FR2785284B1 (fr) * 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
FR2801307B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
FR2801305B1 (fr) 1999-11-24 2002-12-06 Galderma Res & Dev Analogues de la vitamine d
FR2825087B1 (fr) 2001-05-22 2005-01-14 Galderma Res & Dev Analogues de la vitamine d
FR2833258B1 (fr) 2001-12-10 2004-08-27 Galderma Res & Dev Analogues de la vitamine d
US7655717B2 (en) * 2002-07-17 2010-02-02 Mary J. Goulbourne Ointment composition for treating decubitus ulcers and methods for its making and its use
PL378172A1 (pl) * 2003-02-05 2006-03-06 Galderma Research & Development, S.N.C. Kompozycja typu odwrotnej emulsji, zawierająca co najmniej jeden aktywny środek wrażliwy na obecność wody, oraz jej zastosowanie w kosmetyce i dermatologii

Also Published As

Publication number Publication date
JP2007511578A (ja) 2007-05-10
EP1686972B1 (en) 2008-03-12
ES2302060T3 (es) 2008-07-01
WO2005053666A1 (en) 2005-06-16
RU2006121973A (ru) 2007-12-27
EP1952808A2 (en) 2008-08-06
BRPI0416311A (pt) 2006-12-26
EP1952808A3 (en) 2008-09-03
CY1107942T1 (el) 2013-09-04
ATE388697T1 (de) 2008-03-15
EP1686972A1 (en) 2006-08-09
PL1686972T3 (pl) 2008-09-30
DE602004012440D1 (de) 2008-04-24
CA2543577A1 (en) 2005-06-16
MXPA06005587A (es) 2006-08-11
AU2004294728A1 (en) 2005-06-16
DK1686972T3 (da) 2008-06-30
DE602004012440T2 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
PL1686972T3 (pl) Kompozycja możliwa do rozpylania dla podawania pochodnych witaminy D
MXPA05013232A (es) Composicion en forma de pulverizador que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa no volatil.
IL165022A0 (en) Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP1435894A4 (en) CYTOPROTECTIVE COMPOUNDS, METHODS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS
HK1089701A1 (en) Use of a cosmetic or pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
WO2004066918A3 (en) Long wear cosmetic composition
EP1471955A4 (en) AEROSOL GENERATOR FOR A MEDICINAL FORMULATION
EP1156770A4 (en) ANTIOXIDANT NATURAL COMPOSITIONS, PROCESS FOR THE PREPARATION AND COSMETIC, PHARMACEUTICAL AND NUTRITIONAL FORMULATIONS OF SAID COMPOSITIONS
AR046642A1 (es) Composicion en forma de spray que comprende un activo farmaceutico, al menos una silicona volatil y una fase aceitosa, no volatil
ZA200403677B (en) Stabilization of sunscreens in cosmetic compositions.
IL173807A0 (en) Amphiphilic antioxidant compounds, mitoquinone derivatives and pharmaceutical compositions containing the same
MY156471A (en) Combination of lycopene, polyphenol and vitamins for the care of keratin material
CY1107033T1 (el) Συνθεση στη μορφη σπρεϊ η οποια περιλαμβανει ενα συνδυασμο προπιονικης κλομπεταζολης και καλσιτριολης, μια αλκοολικη φαση και μια ελαιωδη φαση
PL1771180T5 (pl) Kompozycja w postaci sprayu zawierająca kombinację propionianu klobetazolu i kalcytriolu, fazę alkoholową i fazę olejową
ITMI20031396A1 (it) Composizione per uso farmaceutico o dietetico o cosmetico dotata di attivita' antiossidante.
TW200513264A (en) Remedy and a therapeutic method for periodontal diseases and pulpal diseases
WO2005051353A8 (en) Pharmaceutical formulations comprising voriconazole
WO2008129189A3 (fr) Nouveaux composés carbamates de vitamine c, compositions les comprenant, et utilisations
IT1317818B1 (it) Procedimento per la produzione di componenti per integratorialimentari, formulazioni dietetiche, cosmetiche e farmaceutiche,
SE0300830D0 (sv) New formulations and use thereof
AU2002364684A1 (en) Amphiphilic compounds for pharmaceutical or cosmetic use
WO2006103356A3 (fr) Utilisation de composes inducteurs de la synthese des proteines sirt dans ou pour la preparation d'une composition cosmetique ou pharmaceutique.
ZA200207846B (en) Topical antioxidant vitamin composition for skin care.
HUP0401943A3 (en) The use of 2alfa,3alfa, 17alfa-trihydroxy-5alfa-androstan-6-one as active ingredient for plant development regulation via increasing stress